Alcon files travoprost/timolol combo
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has accepted Alcon's NDA for a fixed combination of travoprost 0.004%/timolol 0.5% (TTFC) for the treatment of glaucoma, the firm announces Jan. 25. According to preliminary data presented at the Royal Hawaiian Eye Meeting in January, TTFC reduced intraocular pressure 2 mmHg more than travoprost alone at 8 a.m. in one study. In two other Phase III studies, TTFC was not statistically different from concomitant therapy at the 8 a.m. time points "and at most of, but not all, the other measured time points." Safety was comparable to concomitant dosing in all three studies. The firm estimates approximately 50% of U.S. glaucoma patients use two or more agents...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.